ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2834

Utility of the Brain Perfusion Single Photon Emission Computed Tomography in Neuropsychiatric Manifestations of Systemic Lupus Erythematosus

Jorge Medina-Rosas1, Murray Urowitz2, Jiandong Su3, Dafna D Gladman4 and Zahi Touma2, 1Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Neuroimaging, neurologic involvement and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:   The diagnosis of Neuropsychiatric Events (NPE) in SLE is challenging and it is mainly based on the physician judgment. Structural brain imaging has limited utility in the assessment of NPE. We aimed to evaluate the utility of Brain perfusion Single Photon Emission Computed Tomography (SPECT), as a functional imaging, in the assessment of NPE.

Methods:   This is a retrospective analysis on data from a single lupus centre. First, all SPECT done at the centre were identified. Second, we determined if the patients had an NPE (as determined by the physician) at the time corresponding to each SPECT. SPECT results were dichotomized as abnormal (hypoperfusion) or normal. Brain anatomical location (frontal, parietal, or others or multiple [4 or more locations]) and laterality (right, left or bilateral) of the SPECT findings were extracted. NPE were divided into focal (seizure, stroke, subarachnoid hemorrhage, aseptic meningitis [AM] or cranial neuropathy [CN]) and diffuse (organic brain syndrome [OBS], psychosis and headache). Patient weighted Sensitivity (Sn), specificity (Sp), Positive Likelihood Ratio (PLR) and Negative Likelihood Ratio (NLR) of the SPECT were determined. LR of 0.5-1 means minimal decrease, 1 no change, 1-2 minimal increase, 2-5 small increase, 5-10 moderate increase and >10 large increase in the likelihood of disease.

Results:   336 SPECT in 162 patients (46% patients had at least one NPE) were identified. 120 (35.7%) SPECT in 75 patients were abnormal (hypoperfusion).  Of 75 patients, 93% were females, 68% Caucasian, 13% Black, 12% Asian, and 7% other ethnicities. Of the 88 NPE, 94.1% were diffuse and 26.7% were focal (Table 1).   The prevalence of individual NPE on the basis of physician definitive diagnosis was 32.7% for headache 9.9% for OBS, 6.8% for psychosis, 5.6% for cranial neuropathy, 4.3% for seizures, 2.5% for stroke and 0.6% for aseptic meningitis. In diffuse NPE, the most commonly affected localizations of the SPECT hypoperfusion were the temporal lobe (18.8%) on the right side (31.5%). In focal NPE, the most commonly affected localizations of the SPECT hypoperfusion were the fronto-parietal (22.2%), temporal (22.2%) and bilateral (44.4%). Among the 3 most prevalent NPE (headache, OBS and psychosis), SPECT was useful only for headache (PLR 1.4, NLR 0.8). For headache, first, the decision to perform a SPECT should be driven by a high suspicion of lupus activity in a patient who met the definition of lupus headache (persistent nonresponsive to narcotic analgesia headache). Second, the definite diagnosis can be confirmed by an abnormal SPECT. Among diffuse and focal NPE, SPECT was useful for diffuse NPE (PLR 1.2, NLR 0.9) but not for focal NPE (PLR 1.0, NLR 1.0) (table 2).

Conclusion:   The decision to perform a SPECT should be driven by a high suspicion of NPE. SPECT can be more helpful in the assessment of diffuse NPE in particular Lupus Headache and OBS/Psychosis.

 

 

Disclosure: J. Medina-Rosas, None; M. Urowitz, None; J. Su, None; D. D. Gladman, AbbVie, Amgen, BMS, Celgene Corporation, Janssen, Novartis, Pfizer, UCB, 2,AbbVie, Amgen, BMS, Celgene Corporation, Janssen, Novartis, Pfizer, UCB, 5; Z. Touma, None.

To cite this abstract in AMA style:

Medina-Rosas J, Urowitz M, Su J, Gladman DD, Touma Z. Utility of the Brain Perfusion Single Photon Emission Computed Tomography in Neuropsychiatric Manifestations of Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/utility-of-the-brain-perfusion-single-photon-emission-computed-tomography-in-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/utility-of-the-brain-perfusion-single-photon-emission-computed-tomography-in-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology